Effect of Tirzepatide on Health‐Related Quality of Life in Japanese Patients With Obesity Disease: Patient‐Reported Outcomes From the SURMOUNT ‐J Study
Authors' conclusion
In Japanese adults with obesity disease, tirzepatide significantly improved HR-QoL over 72 weeks compared with placebo in both physical and psychosocial domains.
Study context
- Population
- Japanese adults with obesity disease without diabetesrandomized 1:1:1
- Participants
- 201 adults
- Comparison
- Tirzepatide 10 mg or 15 mg vs placebo, adjunct to lifestyle modifications
- Tirzepatide 10 mgn = 63
- Tirzepatide 15 mgn = 69
- Placebon = 69reference
- Primary endpoint
- Change from baseline in health-related quality of life (HR-QoL) (IWQOL-Lite-CT and SF-36v2)
- Follow-up
- Week 72
Methodological detailsphase 3, placebo-controlled, prespecified analyses, post hoc correlation analyses
- Phase 3
- Placebo-controlled
- Prespecified analyses
- Post hoc correlation analyses
Primary result
As reported in the abstract
HR-QoL: IWQOL-Lite-CT and SF-36v2
- Both tirzepatide doses significantly improved IWQOL-Lite-CT Physical Function composite, Physical composite, Psychosocial composite and Total scores and SF-36v2 Physical Functioning domain score vs placebo
Further findings
Subgroups by sex, baseline BMI (< 35, ≥ 35 kg/m²) and age (< 65, ≥ 65 years) · Week 72
- No major variations in treatment effect by baseline characteristics
Correlation of weight loss with IWQOL-Lite-CT improvements · Week 72
- Weight loss correlated with IWQOL-Lite-CT improvements across treatment groups (r values up to)
- −0.32
- Several correlations reached statistical significance
- Post hoc analyses
Original publication
Effect of Tirzepatide on Health‐Related Quality of Life in Japanese Patients With Obesity Disease: Patient‐Reported Outcomes From the SURMOUNT ‐J Study. Diabetes Obes Metab. Published 10 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →